TENGION INC (TNGN)

0.00
0.00 (0.00)
OTC
Prev Close 0.00
Open 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.35
Volume 322.50K
Exchange OTC
Shares Outstanding 40.24M
Market Cap 523.20K
Div & Yield N.A. (N.A)

Latest News

Tengion Announces Transactions Totaling $33.6 Million To Advance Its Organ Regeneration Platform™

Tengion Announces Transactions Totaling $33.6 Million To Advance Its Organ Regeneration Platform™

$15 Million Strategic Investment from Celgene Corporation and $18.6 Million Senior Secured Convertible Note Financing with New and Existing Investors

Tengion Announces Clinical Progress For Neo-Urinary Conduit™ Phase 1 Trial And Regulatory Advance For Neo-Kidney Augment™

Tengion Announces Clinical Progress For Neo-Urinary Conduit™ Phase 1 Trial And Regulatory Advance For Neo-Kidney Augment™

-- Seventh Patient Implanted in Neo-Urinary Conduit Phase 1 Clinical Trial; On Track to Complete Enrollment by End of First Quarter 2013 --

Tengion Provides Patient Update On Its Neo-Urinary Conduit™ Clinical Program

Tengion Provides Patient Update On Its Neo-Urinary Conduit™ Clinical Program

-- Company Reports Unrelated Deaths of Two Patients in its Ongoing Phase 1 Trial --

Tengion Announces Closing Of $15.0 Million Of Senior Secured Convertible Notes Due 2015

Tengion Announces Closing Of $15.0 Million Of Senior Secured Convertible Notes Due 2015

-- Grants Option to Purchase Up to $20 Million in Additional Principal Amount of Notes --

Tengion Announces Pricing Of $15.0 Million Of Senior Secured Convertible Notes Due 2015

Tengion Announces Pricing Of $15.0 Million Of Senior Secured Convertible Notes Due 2015

-- Expects Net Proceeds to Fund Company's Key Objectives for Lead Programs --

Tengion Announces Bridge Financing And Clinical Progress For Neo-Urinary Conduit™ Clinical Program

Tengion Announces Bridge Financing And Clinical Progress For Neo-Urinary Conduit™ Clinical Program

-- Initial $1 Million Loan Expected to Bridge to at Least $15 Million Convertible Debt Financing --

Tengion Common Stock To Begin Trading On The OTCQB™ Tier Of The OTC Marketplace On September 6, 2012

Tengion Common Stock To Begin Trading On The OTCQB™ Tier Of The OTC Marketplace On September 6, 2012

-- The OTCQB is the Home to Approximately 3,500 Companies that are Current in Their Reporting Obligations to the SEC --

Tengion Announces Continued Clinical Progress On Key Milestones For Neo-Urinary Conduit™

Tengion Announces Continued Clinical Progress On Key Milestones For Neo-Urinary Conduit™

-- Fifth Patient Now Implanted in Phase 1 Clinical Trial --

Tengion Announces Reverse Stock Split

Tengion Announces Reverse Stock Split

-- Stock to Begin Trading on a Split-Adjusted Basis on June 14, 2012 --

Tengion Announces Receipt Of NASDAQ Staff Deficiency Letter

Tengion Announces Receipt Of NASDAQ Staff Deficiency Letter

-- Company Expects to Submit Plan to Regain Compliance --

Tengion Announces IND Filing For Neo-Kidney Augment Expected During First Half Of 2013

Tengion Announces IND Filing For Neo-Kidney Augment Expected During First Half Of 2013

-- Anticipated Development Pathway Would Provide Initial Human Proof-of-Concept Data in 2014 --

Tengion Announces Listing Transfer From NASDAQ Global Market® To NASDAQ Capital Market®

Tengion Announces Listing Transfer From NASDAQ Global Market® To NASDAQ Capital Market®

-- Company Will Seek Stockholder Approval of Reverse Stock Split at May Annual Meeting --